Literature DB >> 9888185

Development and validation of a high-performance liquid chromatography tandem mass spectrometry assay for atorvastatin, ortho-hydroxy atorvastatin, and para-hydroxy atorvastatin in human, dog, and rat plasma.

W W Bullen1, R A Miller, R N Hayes.   

Abstract

A liquid chromatographic/mass spectrometric method to quantitate atorvastatin (AT) and its active metabolites ortho-hydroxy (o-AT) and para-hydroxy (p-AT) atorvastatin in human, dog, and rat plasma was validated. The method consisted of washing plasma samples at high pH with diethyl ether and subsequently extracting the analytes and two internal standards, [d5]-atorvastatin ([d5]-AT) and [d5]-ortho-hydroxy atorvastatin ([d5]-o-AT), from acidified plasma by using diethyl ether. The ether layer was evaporated to dryness and the residue reconstituted in ammonium acetate (20 mM, pH 4.0)-acetonitrile-isopropanol (60:40:1, v/v/v). Chromatographic separation of analytes was achieved by using a YMC J'Sphere H80 (C-18) 150 x 2 mm, 4 microns particle size, column with a mobile phase consisting of acetonitrile-0.1% acetic acid, (70:30, v/v). Analytes were detected by using MS/MS. Sample introduction and ionization was by electrospray ionization in the positive ion mode. The method proved suitable for routine quantitation of AT, o-AT, and p-AT over the concentration range of 0.250 to 25.0 ng/mL. Approximate retention time ranges of p-AT, o-AT, [d5]-o-AT, AT, and [d5]-AT were 2.27 +/- 0.21, 3.36 +/- 0.23, 3.54 +/- 0.46, 4.12 +/- 0.61, and 4.65 +/- 0.65 min, respectively. No peaks interfering with quantitation were observed throughout the validation processes. Mean recoveries of AT, o-AT, and p-AT from plasma ranged 100%-107%, 70.6%-104%, and 47.6%-85.6%, respectively. Mean recoveries of the [d5]-AT and [d5]-o-AT internal standards ranged 98.0%-99.9% and 97.3%, respectively. Interassay precision, based on the percent relative deviation for replicate quality controls for AT, o-AT, and p-AT, was < or = 7.19%, 8.28%, and 12.7%, respectively. Interassay accuracy for AT, o-AT, and p-AT was +/- 10.6%, 5.86%, and 15.8%, respectively. AT, o-AT, and p-AT in human, dog, and rat plasma quality controls were stable to three freeze-thaw cycles. AT, o-AT, and p-AT were stable frozen for 127, 30 and 270 days in human, dog, and rat plasma quality control samples, respectively. Human plasma quality control samples containing AT, o-AT, and p-AT were stable for at least 4 days at ambient room temperature and 37 degrees C. The lower limit of quantitation for all analytes was 0.250 ng/mL for a 1.0-mL sample aliquot.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9888185     DOI: 10.1016/S1044-0305(98)00118-4

Source DB:  PubMed          Journal:  J Am Soc Mass Spectrom        ISSN: 1044-0305            Impact factor:   3.109


  7 in total

1.  Simultaneous determination of tenidap and its stable isotope analog in serum by high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry.

Authors:  M J Avery; D Y Mitchell; F C Falkner; H G Fouda
Journal:  Biol Mass Spectrom       Date:  1992-07

2.  Quantitation of SR 27417 in human plasma using electrospray liquid chromatography-tandem mass spectrometry: A study of ion suppression.

Authors:  D L Buhrman; P I Price; P J Rudewiczcor
Journal:  J Am Soc Mass Spectrom       Date:  1996-11       Impact factor: 3.109

3.  Microsample determination of lovastatin and its hydroxy acid metabolite in mouse and rat plasma by liquid chromatography/ionspray tandem mass spectrometry.

Authors:  Y Wu; J Zhao; J Henion; W A Korfmacher; A P Lapiguera; C C Lin
Journal:  J Mass Spectrom       Date:  1997-04       Impact factor: 1.982

4.  Determination of SQ 33,600, a phosphinic acid containing HMG CoA reductase inhibitor, in human serum by high-performance liquid chromatography combined with ionspray mass spectrometry.

Authors:  D Wang-Iverson; M E Arnold; M Jemal; A I Cohen
Journal:  Biol Mass Spectrom       Date:  1992-04

5.  Rapid determination of methandrostenolone in equine urine by isotope dilution liquid chromatography-tandem mass spectrometry.

Authors:  O Edlund; L Bowers; J Henion; T R Covey
Journal:  J Chromatogr       Date:  1989-12-29

6.  Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.

Authors:  R G Bakker-Arkema; M H Davidson; R J Goldstein; J Davignon; J L Isaacsohn; S R Weiss; L M Keilson; W V Brown; V T Miller; L J Shurzinske; D M Black
Journal:  JAMA       Date:  1996-01-10       Impact factor: 56.272

7.  Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.

Authors:  J W Nawrocki; S R Weiss; M H Davidson; D L Sprecher; S L Schwartz; P J Lupien; P H Jones; H E Haber; D M Black
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-05       Impact factor: 8.311

  7 in total
  9 in total

Review 1.  Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.

Authors:  Russell A Wilke; Debbie W Lin; Dan M Roden; Paul B Watkins; David Flockhart; Issam Zineh; Kathleen M Giacomini; Ronald M Krauss
Journal:  Nat Rev Drug Discov       Date:  2007-11       Impact factor: 84.694

2.  Drug-Drug Interactions among Kidney Transplant Recipients in The Outpatient Setting.

Authors:  O Moradi; I Karimzadeh; D Davani-Davari; M Shafiekhani; M M Sagheb; G A Raees-Jalali
Journal:  Int J Organ Transplant Med       Date:  2020

3.  Use of ultra high performance liquid chromatography-tandem mass spectrometry to demonstrate decreased serum statin levels after extracorporeal LDL-cholesterol elimination.

Authors:  M Bláha; H Vlcková; L Nováková; D Solichová; P Solich; M Lánská; J Malý; V Bláha
Journal:  J Biomed Biotechnol       Date:  2010-11-07

4.  Stability Indicating RP-HPLC Estimation of Atorvastatin Calcium and Amlodipine Besylate in Pharmaceutical Formulations.

Authors:  D A Shah; K K Bhatt; R S Mehta; S L Baldania; T R Gandhi
Journal:  Indian J Pharm Sci       Date:  2008-11       Impact factor: 0.975

5.  Simultaneous determination of atorvastatin, metformin and glimepiride in human plasma by LC-MS/MS and its application to a human pharmacokinetic study.

Authors:  Srinivasa Rao Polagani; Nageswara Rao Pilli; Ramakrishna Gajula; Venkateswarlu Gandu
Journal:  J Pharm Anal       Date:  2012-10-03

6.  Simultaneous quantitation of atorvastatin and its two active metabolites in human plasma by liquid chromatography/(-) electrospray tandem mass spectrometry.

Authors:  Pankaj Partani; S Manaswita Verma; Sanjay Gurule; Arshad Khuroo; Tausif Monif
Journal:  J Pharm Anal       Date:  2013-09-25

7.  Simultaneous Determination of Atorvastatin and Aspirin in Human Plasma by LC-MS/MS: Its Pharmacokinetic Application.

Authors:  Ramakrishna Gajula; Nageswara Rao Pilli; Vasu Babu Ravi; Rambabu Maddela; Jaswanth Kumar Inamadugu; Srinivasa Rao Polagani; Sobha Busa
Journal:  Sci Pharm       Date:  2012-08-06

8.  Stress Degradation Behavior of Atorvastatin Calcium and Development of a Suitable Stability-Indicating LC Method for the Determination of Atorvastatin, its Related Impurities, and its Degradation Products.

Authors:  Pallavi Vukkum; J Moses Babu; R Muralikrishna
Journal:  Sci Pharm       Date:  2012-10-09

9.  Performance evaluation of a novel potentiometric membrane sensor for determination of atorvastatin in pharmaceutical preparations.

Authors:  Farhad Ahmadi; Nasim Asaadi
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.